HALO - Halozyme Therapeutics, Inc.
| Previous Close | 17.10 |
| Open | 17.14 |
| Bid | 11.20 x 800 |
| Ask | 18.00 x 3100 |
| Day's Range | 16.92 - 17.21 |
| 52 Week Range | 11.41 - 21.48 |
| Volume | 353,703 |
| Avg. Volume | 745,131 |
| Market Cap | 2.464B |
| Beta | 3.25 |
| PE Ratio (TTM) | 36.00 |
| EPS (TTM) | 0.48 |
| Earnings Date | Nov 5, 2018 - Nov 9, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.38 |
- Thomson Reuters StreetEvents•18 hours ago
Edited Transcript of HALO earnings conference call or presentation 7-Aug-18 8:30pm GMT
Q2 2018 Halozyme Therapeutics Inc Earnings Call
Market Realist•2 days agoArray BioPharma Posted Net Loss of $52.4 Million in Q4
On August 14, Array BioPharma (ARRY) announced its fourth quarter and full fiscal 2018 results for the period ended June 30, 2018. The adjusted EPS (earnings per share) for the fourth quarter came in at -$0.17, exceeding analysts’ estimate of -$0.21. Net loss in the fourth quarter of fiscal 2018 was $52.4 million as compared to $29.6 million losses reported in the fourth quarter of fiscal 2017.
Market Realist•2 days agoWhat Analysts Recommend for Array BioPharma Stock
Array BioPharma (ARRY) announced its fourth-quarter and full fiscal 2018 results on August 14. That day, ARRY stock registered a decline of ~2.6% and fell further the following day. The decline in stock prices was triggered by the negative investor sentiments due to the Array BioPharma’s fourth-quarter results falling short of estimates. In this article, we’ll look at analysts’ latest recommendations and target prices on ARRY stock over the next 12 months.
Markit•5 days agoSee what the IHS Markit Score report has to say about Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc NASDAQ/NGS:HALO
- Zacks•11 days ago
Halozyme Therapeutics (HALO) Reports Q2 Loss, Tops Revenue Estimates
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 27.27% and 11.79%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•12 days ago
Halozyme Therapeutics: 2Q Earnings Snapshot
The San Diego-based company said it had a loss of 16 cents per share. The biopharmaceutical company posted revenue of $35.2 million in the period. Halozyme Therapeutics shares have declined 13 percent ...
- PR Newswire•12 days ago
Halozyme Reports Second Quarter 2018 Results
-- Revenue of $35.2 Million Includes a 36 Percent Increase in Royalty Revenue on a Reported Basis -- -- FDA Accepts Roche/Genentech's Filing for Subcutaneous Formulation of Herceptin® in Combination with ...
- ACCESSWIRE•12 days ago
Halozyme Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 4:30 PM Eastern ...
Markit•15 days agoSee what the IHS Markit Score report has to say about Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc NASDAQ/NGS:HALO
- ACCESSWIRE•18 days ago
Today's Research Reports on Trending Tickers: Halozyme Therapeutics and Repligen
NEW YORK, NY / ACCESSWIRE / August 1, 2018 / Wall Street snapped its losing streak on Tuesday as investors digested better-than-expected quarterly earnings and after the Trump administration appeared to ...
- PR Newswire•24 days ago
Halozyme Therapeutics To Participate In Upcoming Healthcare Conference
SAN DIEGO , July 26, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will be presenting at the Canaccord ...
- PR Newswire•24 days ago
Phase 3 Study Of Subcutaneous Pertuzumab And Trastuzumab Initiated Using Halozyme's ENHANZE® Technology
SAN DIEGO, July 26, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that Genentech, a member of the Roche Group, has dosed the first patient in a Phase 3 study of a fixed-dose combination of pertuzumab (Perjeta®) and trastuzumab (Herceptin®) for subcutaneous administration using Halozyme's proprietary ENHANZE® drug-delivery technology in combination with chemotherapy.
- PR Newswire•last month
FDA Accepts Biologics License Application For Subcutaneous Formulation Of Herceptin
SAN DIEGO , July 11, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application from Genentech, ...
- PR Newswire•last month
Halozyme To Host Second Quarter 2018 Financial Results Conference Call
SAN DIEGO , July 6, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference ...
Markit•2 months agoSee what the IHS Markit Score report has to say about Halozyme Therapeutics Inc.
Short interest is moderate for HALO with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on June 26. Over the last month, growth of ETFs holding HALO is favorable, with net inflows of $5.50 billion.
- Simply Wall St.•2 months ago
How Did Halozyme Therapeutics Inc’s (NASDAQ:HALO) 25.81% ROE Fare Against The Industry?
This article is intended for those of you who are at the beginning of your investing journey and want to begin learning the link between Halozyme Therapeutics Inc (NASDAQ:HALO)’s returnRead More...
- ACCESSWIRE•2 months ago
Free Technical Research on ImmunoGen and Three More Biotech Equities
On Thursday, June 21, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Eight out of nine sectors ended Thursday's trading session in bearish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Grifols S.A. (NASDAQ: GRFS), Halozyme Therapeutics Inc. (NASDAQ: HALO), ImmunoCellular Therapeutics Ltd (NYSE AMER: IMUC), and ImmunoGen Inc. (NASDAQ: IMGN).
- GlobeNewswire•2 months ago
Report: Exploring Fundamental Drivers Behind Virtu Financial, Littelfuse, Gogo, Brookfield Asset Management, Protalix BioTherapeutics, and Halozyme Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, June 13, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Virtu ...
- PR Newswire•2 months ago
Halozyme President And Chief Executive Officer, Dr. Helen Torley Named EY Entrepreneur Of The Year 2018 San Diego
SAN DIEGO, June 11, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced Dr. Helen Torley, president and chief executive officer, was awarded the honor of Entrepreneur Of The Year® 2018 San Diego in the category of Operational Excellence by a panel of independent judges. The EY Entrepreneur Of The Year program recognizes the endeavors of exceptional entrepreneurs who are excelling in areas such as innovation, financial performance and personal commitment to their businesses and communities. "Under Helen's leadership, Halozyme has not only made significant progress growing the ENHANZE technology franchise and studying the potential for our investigational oncology drug, but also in strengthening our culture and commitment to excellence.
Markit•2 months agoSee what the IHS Markit Score report has to say about Halozyme Therapeutics Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- PR Newswire•3 months ago
Halozyme Identifies Plasma Biomarkers As Potential Predictors Of Survival In Pancreatic Cancer
-- Janssen Presenting Five Clinical Studies of subcutaneous daratumumab with Halozyme ENHANZE Technology-- SAN DIEGO , June 1, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology ...
- PR Newswire•3 months ago
Halozyme Therapeutics To Participate In Upcoming Healthcare Conferences
SAN DIEGO , May 29, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies will participate in two upcoming investor ...
- Investor's Business Daily•3 months ago
Halozyme Therapeutics Clears Technical Benchmark, Hitting 80-Plus RS Rating
On Thursday, Halozyme Therapeutics (HALO) earned a positive adjustment to its Relative Strength (RS) Rating, from 80 to 83. [ibd-display-video id=3105496 width=50 float=left autostart=true] When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
- ACCESSWIRE•3 months ago
Today's Research Reports on Trending Tickers: OPKO Health and Halozyme Therapeutics
NEW YORK, NY / ACCESSWIRE / May 15, 2018 / Major U.S. markets closed up on Monday, with the Dow Jones posting its 8th consecutive daily gain, as trade tensions between U.S. and China eased. The Dow Jones ...
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of HALO earnings conference call or presentation 10-May-18 8:30pm GMT
Q1 2018 Halozyme Therapeutics Inc Earnings Call
